[Lys5,MeLeu9,Nle10]Neurokinin A(4-10)

Modify Date: 2024-01-12 17:18:52

[Lys5,MeLeu9,Nle10]Neurokinin A(4-10) structure	Common Name	[Lys5,MeLeu9,Nle10]Neurokinin A(4-10)
	CAS Number	149270-28-0	Molecular Weight	804.97
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₃₉H₆₄N₈O₁₀	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of [Lys5,MeLeu9,Nle10]Neurokinin A(4-10)

[Lys5,MeLeu9,Nle10]Neurokinin A(4-10) (LMN-NKA), an analogue of Neurokinin A, is a selective and potent NK2R agonist. [Lys5,MeLeu9,Nle10]Neurokinin A(4-10) has prokinetic activity. [Lys5,MeLeu9,Nle10]Neurokinin A(4-10) can be used to study the roles of the NK-2 receptor in smooth muscle contraction in numerous tissues[1][2][3].

Name	[Lys5,MeLeu9,Nle10]Neurokinin A(4-10)

Description	[Lys5,MeLeu9,Nle10]Neurokinin A(4-10) (LMN-NKA), an analogue of Neurokinin A, is a selective and potent NK2R agonist. [Lys5,MeLeu9,Nle10]Neurokinin A(4-10) has prokinetic activity. [Lys5,MeLeu9,Nle10]Neurokinin A(4-10) can be used to study the roles of the NK-2 receptor in smooth muscle contraction in numerous tissues[1][2][3].
Related Catalog	Signaling Pathways >> Neuronal Signaling >> Neurokinin Receptor Research Areas >> Neurological Disease Signaling Pathways >> GPCR/G Protein >> Neurokinin Receptor
Target	NK2
In Vivo	[Lys5,MeLeu9,Nle10]Neurokinin A(4-10) (30-100 μg/kg，皮下注射) 增加了小型猪的膀胱和结肠直肠压力峰值[1]。 [Lys5,MeLeu9,Nle10]Neurokinin A(4-10) (0.3 μg/kg 静脉注射或 100 μg/kg 鼻腔吸入) 也会增加膀胱和结肠直肠压力[1]。 [Lys5,MeLeu9,Nle10]Neurokinin A(4-10) (10-100 μg/kg，静脉注射，每天四次，连续六天) 在有意识的狗中引起排尿和排便、呕吐和低血压[2]. Animal Model: Anesthetized minipigs[1] Dosage: 30-100 μg/kg Administration: Subcutaneous injection (s.c.) Result: Showed significant, non-linear, dose-dependent increase in peak bladder and colorectal pressures, and was blocked by GR 159897 (HY-107691)(1 mg/kg i.v., 15 min prior to LMN-NKA). Animal Model: Conscious dogs[2] Dosage: 10-100 μg/kg Administration: Intravenous injection (i.v.), four times daily for six consecutive days. Result: Elicited NK2 receptor-mediated micturition defecation and NK1 receptor-mediated emesis and hypotension.
References	[1]. Rupniak NMJ, et al. Prokinetic effects of the neurokinin NK2 receptor agonist [Lys5,MeLeu9,Nle10]-NKA(4-10) on bladder and colorectal activity in minipigs. Neuropeptides. 2019 Oct;77:101956. [2]. Rupniak NMJ, et al. [Lys5,MeLeu9,Nle10]-NKA(4-10) Elicits NK2 Receptor-Mediated Micturition and Defecation, and NK1 Receptor-Mediated Emesis and Hypotension, in Conscious Dogs. J Pharmacol Exp Ther. 2018 Jul;366(1):136-144. [3]. Sara Good, et al. [Lys5, MeLeu9, Nle10]NKA-4-10. Reference Module in Biomedical Sciences. 2019.

Molecular Formula	C₃₉H₆₄N₈O₁₀
Molecular Weight	804.97

[Lys5,MeLeu9,Nle10]Neurokinin A(4-10)

Use of [Lys5,MeLeu9,Nle10]Neurokinin A(4-10)

Names

[Lys5,MeLeu9,Nle10]Neurokinin A(4-10) Biological Activity

Chemical & Physical Properties